


=> d l1; d his; log y
L1 HAS NO ANSWERS
L1 STR



G1 C,N
G2 H,AK
G3 H,OH,O

Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 17:59:56 ON 17 JUL 2003)

FILE 'REGISTRY' ENTERED AT 18:00:06 ON 17 JUL 2003

L1 STRUCTURE uploaded
L2 0 S L1
L3 54 S L1 FUL

FILE 'CAPLUS' ENTERED AT 18:00:34 ON 17 JUL 2003


L4 1 S L3

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.95	153.31
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.65	-0.65

STN INTERNATIONAL LOGOFF AT 18:01:07 ON 17 JUL 2003

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS
 AN 2002:449494 CAPLUS
 DN 137:37642
 TI Preparation and formulation of a quinolinone compound for treatment of airway disorders
 IN Cuenoud, Bernard; Fairhurst, Robin Alec; Lowther, Nicholas
 PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft mbH; Novartis Pharma GmbH
 SO PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002045703	A2	20020613	WO 2001-EP14122	20011203
	WO 2002045703	A3	20030313		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR			
PRAI	AU 2002017082	A5	20020618	AU 2002-17082	20011203
	GB 2000-29562	A	20001204		
	WO 2001-EP14122	W	20011203		
OS	MARPAT	137:37642			
GI					




I

- AB An inhalation compn. comprises, sep. or together, (A) a quinolinone compd. (I) in free or pharmaceutically acceptable salt or solvate form and (B) a corticosteroid, useful for simultaneous, sequential or sep. administration in the treatment of an inflammatory or obstructive airway disease. The molar ratio of (A) to (B) is from 100:1 to 1:300. A compn. is an aerosol or a dry powder in a capsule. For example, an aerosol formulation was prep'd. by dispensing 10 parts of micronized I maleate, 10 parts of mometasone furoate, and 100 parts of lactose (bulking agent) into a vial, sealing the vial with a metering valve, injecting the premix of 2500 parts of ethanol, 30,500 parts of propellant HFA134a, 67,000 parts of propellant HFA227, and 0.5 parts of oleic acid (surfactant) into the vial through the valve, and subjecting the vial to ultrasonic energy to disperse the solid particles.
- IT 435273-75-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)(prep'n. and quinolinone compd. and formulation in combination with corticosteroid for treatment of airway disorders)

RN 435273-75-9 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 312753-06-3P 435273-74-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and quinolinone compd. and its formulation with corticosteroid for treatment of airway disorders)

RN 312753-06-3 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 435273-74-8 CAPLUS


CN 2(1H)-Quinolinone, 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-, (2Z)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 312753-06-3

CMF C24 H28 N2 O3


Absolute stereochemistry.



CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.




L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
 AN 2000:881125 CAPLUS
 DN 134:42074
 TI Preparation of indanyl-substituted quinolinone derivatives as .beta.2-adrenoceptor agonists
 IN Cuenoud, Bernard; Bruce, Ian; Fairhurst, Robin Alec; Beattie, David
 PA Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
 SO PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000075114	A1	20001214	WO 2000-EP5058	20000602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
BR 2000011324	A	20020305	BR 2000-11324	20000602
EP 1183240	A1	20020306	EP 2000-935163	20000602
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003501417	T2	20030114	JP 2001-501595	20000602
NO 2001005912	A	20020121	NO 2001-5912	20011203
PRAI GB 1999-13083	A	19990604		
WO 2000-EP5058	W	20000602		
OS MARPAT 134:42074				
GI				



Q=



AB The title compds. I [Ar = Q; R1 = H, OH, alkoxy; R2, R3 = H, alkyl; R4-R7 = H, halo, cyano, aryl, etc.; R8 = halo, OR13, etc.; R9 = H or part of a heterocycle; R10 = OR19, NHR19, etc.; X = halo, halomethyl, alkyl; Y = C, N; n = 1, 2; p = 0, 1; q, m = 0, 1], .beta.2-adrenoceptor agonists, were prep'd. E.g., 5-[2-(5,6-dimethoxyindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1H-quinolin-2-one was prep'd.

IT 312753-06-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of indanyl-substituted quinolinone derivs. and related compds. as .beta.2-adrenoceptor agonists)

RN 312753-06-3 CAPLUS

UNIVERSITY

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 312753-05-2P 312753-07-4P 312753-08-5P
 312753-09-6P 312753-10-9P 312753-11-0P
 312753-12-1P 312753-13-2P 312753-14-3P
 312753-16-5P 312753-17-6P 312753-18-7P
 312753-19-8P 312753-20-1P 312753-22-3P
 312753-23-4P 312753-24-5P 312753-26-7P
 312753-31-4P 312753-32-5P 312753-33-6P
 312753-35-8P 312753-36-9P 312753-42-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of indanyl-substituted quinolinone derivs. and related compds. as .beta.-adrenoceptor agonists)

RN 312753-05-2 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(2,3-dihydro-4,7-dimethoxy-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



elected

546/157


514/312

● HCl

RN 312753-07-4 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(2,3-dihydro-5,6-dimethyl-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312753-08-5 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(4,7-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312753-09-6 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(2,3,5,6,7,8-hexahydro-1H-benz[f]inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312753-10-9 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[(1R)-1-hydroxy-2-[(2,3,7,8-tetrahydro-6H-indeno[5,6-b]-1,4-dioxin-7-yl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312753-11-0 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(5,6-dibutyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312753-12-1 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(2,3-dihydro-5,6-dipropyl-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312753-13-2 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[(1R)-1-hydroxy-2-[(6,7,8,9-tetrahydro-5H-benzocyclohepten-7-yl)amino]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312753-14-3 CAPLUS


CN 2(1H)-Quinolinone, 5-[(1R)-2-[[2,3-dihydro-5,6-bis(methoxymethyl)-1H-inden-2-yl]amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 312753-16-5 CAPLUS

CN 2(1H)-Quinolinone, 5-[2-[(2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)




RN 312753-17-6 CAPLUS


CN 2(1H)-Quinolinone, 5-[2-[(2,3-dihydro-5,6-dimethoxy-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)




RN 312753-18-7 CAPLUS
CN 2(1H)-Quinolinone, 5-[2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-
1-
hydroxyethyl]-8-hydroxy-3-methyl- (9CI) (CA INDEX NAME)



RN 312753-19-8 CAPLUS
CN 2(1H)-Quinolinone, 5-[2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-
1-
hydroxyethyl]-8-hydroxy-6-methyl- (9CI) (CA INDEX NAME)




RN 312753-20-1 CAPLUS
CN 2(1H)-Quinolinone, 5-[2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-
1-
hydroxyethyl]-3,4-dihydro-8-hydroxy- (9CI) (CA INDEX NAME)



RN 312753-22-3 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-2-methyl-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312753-23-4 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1S)-2-[(4,7-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 312753-24-5 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-1-hydroxy-2-[(6,7,8,9-tetrahydro-5H-benzocyclohepten-7-yl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 312753-26-7 CAPLUS


CN 2(1H)-Quinolinone, 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-, (2Z)-2-butenedioate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 312753-25-6

CMF C24 H28 N2 O2

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 312753-31-4 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(2,3-dihydro-4,5,6,7-tetramethyl-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312753-32-5 CAPLUS


CN 2(1H)-Quinolinone, 5-[(1R)-2-[(2,3-dihydro-2-methyl-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 312753-33-6 CAPLUS

CN 2(1H)-Quinolinone, 5-[2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)



RN 312753-35-8 CAPLUS


CN 2(1H)-Quinolinone, 5-[(1R)-2-[(2,3,5,6,7,8-hexahydro-2-methyl-1H-benz[f]inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 312753-34-7

CMF C25 H28 N2 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 312753-36-9 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1S)-2-[(2,3,5,6,7,8-hexahydro-1H-benz[f]inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312753-42-7 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 312753-63-2P 312753-64-3P 312753-69-8P
 312754-12-4P 312754-14-6P 312754-19-1P
 312754-22-6P 312754-35-1P 312754-37-3P
 312754-38-4P 312754-39-5P 312759-81-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation);
 RACT (Reactant or reagent)
 (prepn. of indanyl-substituted quinolinone derivs. and related compds.
 as .beta.2-adrenoceptor agonists)


RN 312753-63-2 CAPLUS

CN 2(1H)-Quinolinone, 5-[(2,3-dihydro-1H-inden-2-yl)amino]acetyl]-8-hydroxy- (9CI) (CA INDEX NAME)




RN 312753-64-3 CAPLUS

CN 2(1H)-Quinolinone, 5-[(2,3-dihydro-5,6-dimethoxy-1H-inden-2-yl)amino]acetyl]-8-hydroxy- (9CI) (CA INDEX NAME)



RN 312753-69-8 CAPLUS


CN 2(1H)-Quinolinone, 5-[2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-3-methyl-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 312754-12-4 CAPLUS


CN 2(1H)-Quinolinone, 5-[(1R)-2-[(2,3-dihydro-4,7-dimethoxy-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 312754-14-6 CAPLUS


CN 2(1H)-Quinolinone, 5-[2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-(methoxymethoxy)-6-methyl- (9CI) (CA INDEX NAME)



RN 312754-19-1 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(5,6-diethyl-2,3-dihydro-2-methyl-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312754-22-6 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-1-hydroxy-2-[(6,7,8,9-tetrahydro-5H-benzocyclohepten-7-yl)amino]ethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312754-35-1 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(2,3-dihydro-4,5,6,7-tetramethyl-1H-inden-2-yl) (phenylmethyl) amino]-1-hydroxyethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312754-37-3 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(2,3-dihydro-2-methyl-1H-inden-2-yl) amino]-1-hydroxyethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312754-38-4 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1R)-2-[(2,3,5,6,7,8-hexahydro-2-methyl-1H-benz[f]inden-2-yl) amino]-1-hydroxyethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312754-39-5 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1S)-2-[(2,3,5,6,7,8-hexahydro-1H-benz[f]inden-2-yl)(phenylmethyl)amino]-1-hydroxyethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 312759-81-2 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1S)-2-[(5,6-diethyl-2,3-dihydro-1H-inden-2-yl)amino]-1-hydroxyethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
 AN 1994:217308 CAPLUS
 DN 120:217308
 TI Preparation of carbostyryl derivatives as bronchodilators
 IN Tsuchiya, Susumu; Mori, Hiroaki; Hiratsuka, Kouzou; Takenawa, Noriko
 PA Tokyo Tanabe Co. Ltd., Japan
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9318007	A1	19930916	WO 1993-JP303	19930312
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9336487	A1	19931005	AU 1993-36487	19930312
PRAI	JP 1992-54733		19920313		
	WO 1993-JP303		19930312		
OS	MARPAT 120:217308				
GI					



AB The title compds. I [OY = OH, (substituted) alkoxy, protected OH; Z = H, OH, alkoxy, etc; dotted line indicates either single or double bond] were prep'd. I are bronchodilators which selectively act upon the .beta.2-adrenaline receptor. Reaction of oxiranylcabostyryl II with aminotetralin III gave title compd. IV. In a test using tracheal muscles isolated from guinea pigs, IV caused the relaxation of the said muscles and had ED50 value of 0.11 nM vs. ED50 value of 0.19 nM for procaterol.


IT 153388-00-2P 153388-01-3P 153388-02-4P
 153388-03-5P 153388-04-6P 153388-05-7P
 153388-06-8P 153388-07-9P 153388-08-0P
 153388-09-1P 153388-10-4P 153388-11-5P
 153388-12-6P 153388-13-7P 153388-14-8P
 153388-15-9P 153388-16-0P 153388-17-1P
 153388-18-2P 153388-19-3P 153388-20-6P
 153388-21-7P 153388-22-8P 153388-23-9P
 153388-24-0P 153388-25-1P 153388-26-2P
 153388-27-3P 153388-28-4P 153388-29-5P
 153388-30-8P 153388-31-9P 153388-32-0P
 153388-33-1P 153388-34-2P 153388-35-3P
 153388-36-4P 153388-37-5P 153388-38-6P

153388-39-7P 153388-40-0P 153388-41-1P
153388-42-2P 153388-43-3P 153388-44-4P
153388-45-5P 153388-46-6P 153388-47-7P
153388-48-8P 153388-49-9P 153388-50-2P
153388-51-3P 153388-52-4P 153388-53-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as bronchodilator)


RN 153388-00-2 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 153388-01-3 CAPLUS

CN 2(1H)-Quinolinone, 5-[2-[(7-ethoxy-1,2,3,4-tetrahydro-2-naphthalenyl)amino]-1-hydroxyethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 153388-02-4 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[[1,2,3,4-tetrahydro-7-(pentyloxy)-2-naphthalenyl]amino]ethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 153388-03-5 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 153388-04-6 CAPLUS

CN 2(1H)-Quinolinone, 5-[2-[(7-ethoxy-1,2,3,4-tetrahydro-2-naphthalenyl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)




RN 153388-05-7 CAPLUS
CN 2 (1H)-Quinolinone, 5-[2-[(7-ethoxy-1,2,3,4-tetrahydro-2-naphthalenyl)amino]-1-hydroxyethyl]-8-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 153388-06-8 CAPLUS
CN 2 (1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[1,2,3,4-tetrahydro-7-(pentyloxy)-2-naphthalenyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 153388-07-9 CAPLUS
CN 2 (1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[1,2,3,4-tetrahydro-7-(pentyloxy)-2-naphthalenyl]amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 153388-08-0 CAPLUS
CN 2 (1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-hydroxy-2-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 153388-09-1 CAPLUS


CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-hydroxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-10-4 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-methoxy- (9CI) (CA INDEX NAME)



RN 153388-11-5 CAPLUS


CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 153388-12-6 CAPLUS


CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)



RN 153388-13-7 CAPLUS
 CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 153388-14-8 CAPLUS
 CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 153388-15-9 CAPLUS
 CN Acetic acid, [[7-[[2-[1,2-dihydro-2-oxo-8-(phenylmethoxy)-5-quinolinyl]-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 153388-16-0 CAPLUS
 CN Acetic acid, [[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 153388-17-1 CAPLUS


CN Acetic acid, [[7-[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-18-2 CAPLUS

CN Acetic acid, [[5,6,7,8-tetrahydro-7-[2-hydroxy-2-(1,2,3,4-tetrahydro-8-hydroxy-2-oxo-5-quinolinyl)ethyl]amino]-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 153388-19-3 CAPLUS


CN Acetic acid, [[5,6,7,8-tetrahydro-7-[2-hydroxy-2-(1,2,3,4-tetrahydro-8-hydroxy-2-oxo-5-quinolinyl)ethyl]amino]-2-naphthalenyl]oxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-20-6 CAPLUS

CN Acetamide, 2-[[7-[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



RN 153388-21-7 CAPLUS


CN Acetamide, 2-[[7-[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-22-8 CAPLUS

CN Acetamide, 2-[[7-[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-N-ethyl-, (9CI) (CA INDEX NAME)



RN 153388-23-9 CAPLUS


CN Acetamide, 2-[[7-[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-24-0 CAPLUS

CN Butanoic acid, 4-[[7-[2-[1,2-dihydro-2-oxo-8-(phenylmethoxy)-5-quinolinyl]-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 153388-25-1 CAPLUS

CN Butanoic acid, 4-[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 153388-26-2 CAPLUS


CN Butanoic acid, 4-[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-27-3 CAPLUS

CN Pentanoic acid, 5-[7-[[2-[1,2-dihydro-2-oxo-8-(phenylmethoxy)-5-quinolinyl]-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 153388-28-4 CAPLUS

CN Pentanoic acid, 5-[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 153388-29-5 CAPLUS


CN Pentanoic acid, 5-[[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



• HCl


RN 153388-30-8 CAPLUS

CN Hexanoic acid, 6-[[7-[[2-[1,2-dihydro-2-oxo-8-(phenylmethoxy)-5-quinolinyl]-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 153388-31-9 CAPLUS

CN Hexanoic acid, 6-[[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 153388-32-0 CAPLUS


CN Hexanoic acid, 6-[[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-33-1 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[[1,2,3,4-tetrahydro-7-[(5-hydroxypentyl)oxy]-2-naphthalenyl]amino]ethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 153388-34-2 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[1,2,3,4-tetrahydro-7-[(5-hydroxypentyl)oxy]-2-naphthalenyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 153388-35-3 CAPLUS


CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[1,2,3,4-tetrahydro-7-[(5-hydroxypentyl)oxy]-2-naphthalenyl]amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 153388-36-4 CAPLUS


CN Hexanoic acid, 6-[[5,6,7,8-tetrahydro-7-[[2-hydroxy-2-(1,2,3,4-tetrahydro-8-hydroxy-2-oxo-5-quinolinyl)ethyl]amino]-2-naphthalenyl]oxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-37-5 CAPLUS

CN Hexanoic acid, 6-[[5,6,7,8-tetrahydro-7-[[2-hydroxy-2-(1,2,3,4-tetrahydro-8-hydroxy-2-oxo-5-quinolinyl)ethyl]amino]-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 153388-38-6 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 153388-39-7 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153388-40-0 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-

naphthalenyl)amino]ethyl]-8-(phenylmethoxy)-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153388-41-1 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153388-42-2 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 153388-43-3 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153388-44-4 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride, [R-(R*,R*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




• HCl

RN 153388-45-5 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)-, [S-(R*,R*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153388-46-6 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)-, [R-(R*,S*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153388-47-7 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-

methoxy-2-naphthalenyl)amino]ethyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153388-48-8 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 153388-49-9 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153388-50-2 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 153388-51-3 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 153388-52-4 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 153388-53-5 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenyl)amino]ethyl]-, monohydrobromide (9CI) (CA INDEX NAME)




● HBr

=> d l1; d his; log y

L1 HAS NO ANSWERS

L1 STR



G1 C, N

G2 H, Ak

G3 H, OH, O

Structure attributes must be viewed using STN Express query preparation.

(FILE 'HOME' ENTERED AT 17:44:58 ON 17 JUL 2003)

FILE 'REGISTRY' ENTERED AT 17:45:04 ON 17 JUL 2003

L1 STRUCTURE uploaded

L2 1 S L1

L3 95 S L1 FUL

FILE 'CAPLUS' ENTERED AT 17:45:29 ON 17 JUL 2003

L4 3 S L3

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

14.03

162.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE


-1.95

-1.95

STN INTERNATIONAL LOGOFF AT 17:46:17 ON 17 JUL 2003

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
 AN 1994:217308 CAPLUS
 DN 120:217308
 TI Preparation of carbostyryl derivatives as bronchodilators
 IN Tsuchiya, Susumu; Mori, Hiroaki; Hiratsuka, Kouzou; Takenawa, Noriko
 PA Tokyo Tanabe Co. Ltd., Japan
 SO PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9318007	A1	19930916	WO 1993-JP303	19930312
	W: AU, CA, JP, KR, US			RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE	
	AU 9336487	A1	19931005	AU 1993-36487	19930312
PRAI	JP 1992-54733		19920313		
	WO 1993-JP303		19930312		
OS	MARPAT 120:217308				
GI					



AB The title compds. I [OY = OH, (substituted) alkoxy, protected OH; Z = H, OH, alkoxy, etc; dotted line indicates either single or double bond] were

prep'd. I are bronchodilators which selectively act upon the .beta.2-adrenalin receptor. Reaction of oxiranylcabostyryl II with aminotetralin III gave title compd. IV. In a test using tracheal muscles

isolated from guinea pigs, IV caused the relaxation of the said muscles and had ED50 value of 0.11 nM vs. ED50 value of 0.19 nM for procaterol.


IT 153388-00-2P 153388-01-3P 153388-02-4P
 153388-03-5P 153388-04-6P 153388-05-7P
 153388-06-8P 153388-07-9P 153388-08-0P
 153388-09-1P 153388-10-4P 153388-11-5P
 153388-12-6P 153388-13-7P 153388-14-8P
 153388-15-9P 153388-16-0P 153388-17-1P

153388-18-2P 153388-19-3P 153388-20-6P
153388-21-7P 153388-22-8P 153388-23-9P
153388-24-0P 153388-25-1P 153388-26-2P
153388-27-3P 153388-28-4P 153388-29-5P
153388-30-8P 153388-31-9P 153388-32-0P
153388-33-1P 153388-34-2P 153388-35-3P
153388-36-4P 153388-37-5P 153388-38-6P
153388-39-7P 153388-40-0P 153388-41-1P
153388-42-2P 153388-43-3P 153388-44-4P
153388-45-5P 153388-46-6P 153388-47-7P
153388-48-8P 153388-49-9P 153388-50-2P
153388-51-3P 153388-52-4P 153388-53-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as bronchodilator)


RN 153388-00-2 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 153388-01-3 CAPLUS

CN 2(1H)-Quinolinone, 5-[2-[(7-ethoxy-1,2,3,4-tetrahydro-2-naphthalenyl)amino]-1-hydroxyethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 153388-02-4 CAPLUS


CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[[1,2,3,4-tetrahydro-7-(pentyloxy)-2-naphthalenyl]amino]ethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 153388-03-5 CAPLUS
CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 153388-04-6 CAPLUS
CN 2(1H)-Quinolinone, 5-[2-[(7-ethoxy-1,2,3,4-tetrahydro-2-naphthalenyl)amino]-1-hydroxyethyl]-8-hydroxy- (9CI) (CA INDEX NAME)




RN 153388-05-7 CAPLUS
CN 2(1H)-Quinolinone, 5-[2-[(7-ethoxy-1,2,3,4-tetrahydro-2-naphthalenyl)amino]-1-hydroxyethyl]-8-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



HCl


RN 153388-06-8 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[1,2,3,4-tetrahydro-7-(pentyloxy)-2-naphthalenyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 153388-07-9 CAPLUS


CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[1,2,3,4-tetrahydro-7-(pentyloxy)-2-naphthalenyl]amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-08-0 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-hydroxy-2-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 153388-09-1 CAPLUS


CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-hydroxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-10-4 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-methoxy- (9CI) (CA INDEX NAME)



RN 153388-11-5 CAPLUS


CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-12-6 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 153388-13-7 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 153388-14-8 CAPLUS


CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-2-naphthalenyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-15-9 CAPLUS

CN Acetic acid, [[7-[[2-[1,2-dihydro-2-oxo-8-(phenylmethoxy)-5-quinolinyl]-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 153388-16-0 CAPLUS

CN Acetic acid, [[7-[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 153388-17-1 CAPLUS


CN Acetic acid, [[7-[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 153388-18-2 CAPLUS


CN Acetic acid, [[5,6,7,8-tetrahydro-7-[[2-hydroxy-2-(1,2,3,4-tetrahydro-8-hydroxy-2-oxo-5-quinolinyl)ethyl]amino]-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 153388-19-3 CAPLUS

CN Acetic acid, [[5,6,7,8-tetrahydro-7-[[2-hydroxy-2-(1,2,3,4-tetrahydro-8-hydroxy-2-oxo-5-quinolinyl)ethyl]amino]-2-naphthalenyl]oxy]-, ethyl ester,


monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-20-6 CAPLUS

CN Acetamide, 2-[[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)



RN 153388-21-7 CAPLUS


CN Acetamide, 2-[[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-22-8 CAPLUS

CN Acetamide, 2-[[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-N-ethyl- (9CI) (CA INDEX NAME)



RN 153388-23-9 CAPLUS


CN Acetamide, 2-[[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-24-0 CAPLUS

CN Butanoic acid, 4-[[7-[[2-[1,2-dihydro-2-oxo-8-(phenylmethoxy)-5-quinolinyl]-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 153388-25-1 CAPLUS

CN Butanoic acid, 4-[[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 153388-26-2 CAPLUS


CN Butanoic acid, 4-[[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-27-3 CAPLUS

CN Pentanoic acid, 5-[[7-[[2-[1,2-dihydro-2-oxo-8-(phenylmethoxy)-5-quinolinyl]-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 153388-28-4 CAPLUS

CN Pentanoic acid, 5-[[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 153388-29-5 CAPLUS


CN Pentanoic acid, 5-[[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-30-8 CAPLUS

CN Hexanoic acid, 6-[[7-[[2-[1,2-dihydro-2-oxo-8-(phenylmethoxy)-5-quinolinyl]-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 153388-31-9 CAPLUS

CN Hexanoic acid, 6-[[7-[[2-(1,2-dihydro-8-hydroxy-2-oxo-5-quinolinyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 153388-32-0 CAPLUS


CN Hexanoic acid, 6-[[7-[(2-hydroxyethyl)amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-2-hydroxyethyl]-, ethyl ester,
monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-33-1 CAPLUS

CN 2(1H)-Quinolinone, 5-[(1-hydroxy-2-[(1,2,3,4-tetrahydro-7-[(5-hydroxypentyl)oxy]-2-naphthalenyl]amino)ethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 153388-34-2 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[(1-hydroxy-2-[(1,2,3,4-tetrahydro-7-[(5-hydroxypentyl)oxy]-2-naphthalenyl]amino)ethyl]- (9CI) (CA INDEX NAME)



RN 153388-35-3 CAPLUS


CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[[1,2,3,4-tetrahydro-7-[(5-hydroxypentyl)oxy]-2-naphthalenyl]amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 153388-36-4 CAPLUS


CN Hexanoic acid, 6-[[5,6,7,8-tetrahydro-7-[[2-hydroxy-2-(1,2,3,4-tetrahydro-8-hydroxy-2-oxo-5-quinolinyl)ethyl]amino]-2-naphthalenyl]oxy]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 153388-37-5 CAPLUS

CN Hexanoic acid, 6-[[5,6,7,8-tetrahydro-7-[[2-hydroxy-2-(1,2,3,4-tetrahydro-8-hydroxy-2-oxo-5-quinolinyl)ethyl]amino]-2-naphthalenyl]oxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 153388-38-6 CAPLUS
 CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 153388-39-7 CAPLUS
 CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 153388-40-0 CAPLUS
 CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153388-41-1 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-

2-naphthalenyl)amino]ethyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153388-42-2 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-

2-naphthalenyl)amino]ethyl]-, monohydrochloride, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 153388-43-3 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-

2-naphthalenyl)amino]ethyl]-, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 153388-44-4 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-

2-naphthalenyl)amino]ethyl]-, monohydrochloride, [R-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 153388-45-5 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153388-46-6 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153388-47-7 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153388-48-8 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 153388-49-9 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153388-50-2 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)amino]ethyl]-, monohydrochloride, [R-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 153388-51-3 CAPLUS

CN 2(1H)-Quinolinone, 5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)amino]ethyl]-8-(phenylmethoxy)- (9CI) (CA INDEX NAME)




RN 153388-52-4 CAPLUS

CN 2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 153388-53-5 CAPLUS

CN 2 (1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1,2,3,4-tetrahydro-6-hydroxy-2-naphthalenyl)amino]ethyl]-, monohydrobromide (9CI) (CA INDEX NAME)



● HBr